2018
Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
Somé A, Bazié T, Zongo I, Yerbanga R, Nikiéma F, Neya C, Taho L, Ouédraogo J. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasites & Vectors 2018, 11: 323. PMID: 29843783, PMCID: PMC5975679, DOI: 10.1186/s13071-018-2895-4.Peer-Reviewed Original ResearchConceptsSymptomatic malaria patientsPolymerase chain reactionMalaria patientsAllelic familiesBobo-DioulassoMAD20 allelic familyUrban health centersCause of morbidityMerozoite surface protein 1K1 allelic familySurface protein 1Plasmodium falciparum msp1P. malariaUncomplicated malariaFalciparum infectionResultsA totalHealth centersBlood samplesP. falciparumConclusionsOur studyBlood spotsMalaria parasite populationsAllele frequenciesPatientsBurkina Faso
2007
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa
Parikh S, Ouedraogo J, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa. Clinical Pharmacology & Therapeutics 2007, 82: 197-203. PMID: 17361129, DOI: 10.1038/sj.clpt.6100122.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAmodiaquineAntimalarialsAryl Hydrocarbon HydroxylasesBenzoxazinesBurkina FasoChromatography, High Pressure LiquidCyclopropanesCytochrome P-450 CYP2C8Dose-Response Relationship, DrugDrug InteractionsEnzyme InhibitorsGenotypeHIV Protease InhibitorsHumansLopinavirMalaria, FalciparumModels, BiologicalPolymorphism, GeneticPyridinesPyrimidinonesPyronesReverse Transcriptase InhibitorsSaquinavirSpectrophotometry, UltravioletSulfonamidesTreatment OutcomeTrimethoprimConceptsAntimalarial drug amodiaquineMalaria-infected patientsAntiretroviral drug efavirenzImportant clinical implicationsAmodiaquine metabolismCYP2C8 genotypeMalaria treatmentN-desethylamodiaquineCYP2C8 variantsCYP2C8 activityCYP2C8 inhibitorsDrug interactionsDefective metabolismClinical implicationsCYP2C8Common polymorphismsDrug efavirenzMetabolismRelevant concentrationsDrugsEfficacyPrimary metabolitesAllele frequenciesToxicitySample size